INTRODUCTION
Relaxin (RLX) is a peptide hormone of pregnancy, structurally related to insulin. Two human (h) nonallelic genes have been identified, of which only one, designated gene 2 (h.RLX-2), is expressed in the ovary (Hudson, John, Crawford et al. 1984) . The other form, gene 1 (hRLX-1), has only been found to date in the genome (Hudson, Haley, John et al. 1983) .
The effects of RLX on the uterus, cervix and pubic symphysis of many species are well documented (Hisaw, 1926; McLennan, Green & Greenwood, 1980; Bryant-Greenwood, Niall & Greenwood, 1981; Bryant-Greenwood, 1982; Porter, 1983; Sherwood & Downing, 1983 , Weiss, 1984 . Bioassays have been used for the measurement of RLX activity in the reproductive tract and during pregnancy and nonpregnancy (Steinetz, Beach, Kroc et al. 1960; Sarosi, Schmidt, Essig et al. 1983 ). Although bioassays measure active forms of RLX, their general lack of sensitivity and precision (Sherwood, 1979) has necessitated the development of sensitive and specific immunoassays (Sherwood, Rosentreter & Birkhimer, 1975; O'Byrne & Steinetz, 1976; Loumaye, Teuwissen & Thomas, 1978; Sherwood & Crnekovic, 1979; Sherwood, Crnekovic, Gordon & Rutherford, 1980; Eddie, Lester, Bennett et al. 1986 ). Since corpora lutea during pregnancy are the primary source of hRLX, studies of RLX physiology in man had to rely upon the use of porcine RLX both as antigen for immuno¬ assays and as hormone for physiology studies (Bryant, 1972; Sherwood et al. 1975; O'Byrne & Steinetz, 1976; Loumaye et al. 1978; MacLennan et al. 1980; Bryant-Greenwood et al. 1981; BryantGreenwood, 1982; Porter, 1983; Sherwood & Downing, 1983 , Weiss, 1984 . While iodination of porcine RLX has been hampered by the lack of tyrosine and histidine residues (Sherwood et al. 1975; Loumaye et al. 1978 ; Bryant-Greenwood, 1982; Weiss, 1984) , an accessible tyrosine residue in a synthetic analogue of hRLX has allowed direct iodination and its use in a sensitive radioimmuno¬ assay (RIA) to quantify serum hRLX concentrations during pregnancy (Eddie et al 1986) . Because of the short shelf-life of iodinated hormone used as a tracer in the RIA for hRLX (Eddie et (Johnston, Burnier, Chen et al. 1985) . The hRLX-2 (SKA) analogue contains a chain with a serine (S) as the amino-terminal residue, due to the deletion of the aspartic acid and the substitution of the two methionines at positions 4 and 25 by a lysine ( ) and alanine (A) respectively (see Fig. 1 ). The hRLX-2 (DKA) analogue contains the full length chain with the same methionine substitutions as described for SKA. All three in-vitro chain-combined forms of hRLX have equivalent biological activity (Johnston et al. 1985) in both the murine pubic symphysis ligament (Steinetz et al. 1960 ) and rat uterine contractility (St Louis, 1981 bioassays. Analogue hRLX-2 (SKA) was used as standard and control in the immunoassay. Protein content was determined by quantitative amino acid analysis, using a Beckman 6300 analyser, as previously described (Aggarwal, Henzel, Moffat et al. 1985) . Relaxin was stored lyophilized and dessicated at -20°C. Standards were prepared by diluting into normal human serum (NHS) a stock solution of 10 mg hRLX-2 (SKA)/1 in phosphate-buffered saline (PBS; pH 7-2) containing 0-5% (w/v) bovine serum albumin (BSA) and 0-02% (w/v) sodium azide. They were stored at -60°C.
Controls were prepared by diluting the standard stock solution in NHS to the low, medium and high concen¬ tration range of the standard curve. These were divided into small aliquots and stored at -60°C.
Human corpora luteal RLX Natural hRLX was extracted from corpora lutea of patients with ectopie pregnancies at 7 weeks of ges¬ tation, using a modification of the procedure of Doczi (Drolet, Henzel & Johnston, 1987) using a monoclonal antibody raised to hRLX-2 (SKA) antigen. The hRLX thus obtained was esti¬ mated to be a 6500 Da peptide by its elution position on P-10 gel filtration, to have an amino-terminal sequence identical to hRLX-2, and to be equipotent with synthetic hRLX-2 in an in-vitro cyclic AMP (cAMP)-release bioassay (Drolet et al. 1987 (Gorman, Ross & Niall, 1988 (Good, Woofsy, Kimura & Henry, 1980) followed by affinity chromatography on hRLX-2(SKA) coupled to Affigel 10 (BioRad, Richmond, CA, U.S.A.), prepared according to the manufacturer's instructions. Anti¬ bodies were eluted with glycine-HCl (0-1 mol/1; pH 2-5) and dialysed overnight against PBS (pH 7-4). Pro¬ tein content was estimated by measuring absorbance at 280nm and using an extinction coefficient of 140. The same protocol was followed for the preparation of all subsequent batches of antibody to hRLX-2 (SKA).
Preparation of enzyme-conjugated antibodies to hRLX-2 (SKA) Affinity-purified antibodies to hRLX-2 (SKA) were conjugated to horseradish peroxidase (HRP; Grade I; Boehringer Mannheim, Mannheim, F.R.G.) by the sodium periodate method of Nakane & Pierce (1967 (Gilman, 1970 (Marquardt, 1963 (Blundell, Gowan & Schwabe, 1983 tRefer to Fig. 1 for sequences of each of the synthetic forms of hRLX.
In Fig. 3 , we show the relationship between various forms of hRLX, namely recombinant human pro¬ relaxin, the synthetic native and analogue forms of hRLX-2, and hRLX extracted from corpora lutea from pregnant women. ELISA dilution curves for the various synthetic human relaxins were nearly iden¬ tical to that of purified luteal hRLX, indicating immunological identity between the synthetic peptides and the natural hormone. On the other hand, recom¬ binant human prorelaxin did not dilute in parallel with hRLX-2, and required high concentrations to generate absorbance values similar to those obtained with the other forms of hRLX.
Relaxin concentrations in human samples
Relaxin concentrations were determined in a pooled sample from the plasma of two women (gestational ages of 25 and 36 days from the last menstrual period (LMP)) who were pregnant following in-vitro fertili¬ zation (IVF), in serum samples from three healthy non-pregnant female volunteers, as well as in serum samples from ten healthy male volunteers and in a normal male human plasma pool. Results in Table 3 show no endogenous hRLX in the three plasma samples from non-pregnant women, nor in normal male serum or plasma. In the pooled IVF sample, approximately Fig. 3 by the parallelism between synthetic native hRLX in serum (assay standard), synthetic analogue hRLX-2, corpus luteum-derived hRLX and hRLX in a plasma pool from two IVF pregnancies. The data in Fig. 3 (James, Niall, Kwok & BryantGreenwood, 1977) (Table 2) . Several reproductive peptide hormones did not cross-react in the assay, nor did hGH.
No hRLX was detected in sera from ten men, nor in the three sera from non-pregnant women tested (Table 3) . The hormone has never convincingly been detected in peripheral plasma or serum in men (Loumaye, De Cooman & Thomas, 1980; Loumaye, Donnez & Thomas, 1983; Eddie et al. 1986 ), but has been detected in some cases in sera from non-pregnant women when immunoassays with porcine RLX were used (Thomas, 1982; Weiss, 1984 Table  2 and Fig. 3 . Even though preliminary, this observation of crossplacental transfer of hRLX-2 (SKA) in one rhesus monkey is the first reported for relaxin, and nonanalogue hRLX-2 crosses the rhesus placenta (P. Cossum, personal communication). The observation of cross-placental transfer of insulin has been con¬ tradictory and possibly species dependent (Pitkin & Reynolds, 1969; Widness, Goldman, Susa et al. 1983) .
A transfer of 25-50% of intact insulin has been reported in the rhesus monkey (Pitkins & Reynolds, 1969) , in which the placenta has a marked structural similarity to the human (Ramsey & Harris, 1966) . We observed only 1-3% placental transfer of hRLX-2 (SKA) in one rhesus monkey (Fig. 4) , which is much less than that reported for insulin.
Additional studies will clearly be required to clarify these preliminary results. However, the availability of this easily automated, isotope-free and sensitive assay for the measurement of hRLX should facilitate the study of the physiology of this hormone and of its role in human reproduction. This assay was instru¬ mental in following hRLX immunoactivity during its purification from human sources.
